Results 221 to 230 of about 123,346 (302)

Adjusting for Medication Use in GWAS and Its Impact on Mendelian Randomisation Analyses: An Example of Systolic Blood Pressure in UK Biobank

Genetic Epidemiology, Volume 50, Issue 8, December 2026.
ABSTRACT Medication use is common in large‐scale population cohorts, and can modify phenotypic traits of interest. This can potentially bias effect estimates in genome‐wide association studies (GWAS) and impact downstream analyses such as Mendelian randomisation (MR). The best approach to account for medication use in GWAS is unclear. In this study, we
Aaron Jun Yi Yap, Aimee L. Hanson, Gareth J. Griffith, Eleanor Sanderson   +3 more
wiley   +1 more source

Defining the potential role of the mineralocorticoid receptor in musculoskeletal health and bone crosstalk with other tissues. [PDF]

J Endocrinol
Bensreti H, Shaver JC, Yearwood CL, Alhamad DW, Morey EC, Sultana S, Hamrick MW, Kosmac K, Bollag WB, Belin de Chantemele EJ, Isales CM, McGee-Lawrence ME.   +11 more
europepmc   +1 more source

The Effects of Angiotensin Receptor Neprilysin Inhibitor on Endoplasmic Reticulum Stress in Doxorubicin‐Mediated Cardiomyopathy‐Associated Heart Failure Model in Rats

Journal of Applied Toxicology, Volume 46, Issue 12, Page 4646-4655, December 2026.
ABSTRACT One of the most serious complications associated with the use of the chemotherapeutic agent doxorubicin (DOX) is cardiomyopathy. Although cardioprotective drugs such as angiotensin receptor‐neprilysin inhibitors (ARNI) are used to prevent cardiomyopathy in DOX patients, no studies have reported the relationship between ARNI and endoplasmic ...
Mert Unvan, Meryem İlkay Karagül, Hatice Oruç Demirbağ, Ebru Balli   +3 more
wiley   +1 more source

Subclinical primary aldosteronism: toward a conceptual framework linking primary aldosteronism and low-renin hypertension. [PDF]

Front Endocrinol (Lausanne)
Park CH.
europepmc   +1 more source

Dyslipidaemia, Chronic Kidney Disease and Diabetes Mellitus: A Triple Threat to Cardiovascular Health

Diabetes, Obesity and Metabolism, Volume 28, Issue 12, Page 10961-10976, December 2026.
ABSTRACT Diabetes mellitus (DM) and chronic kidney disease (CKD) frequently coexist and together create a ‘triple threat’ with dyslipidaemia, enhancing the risk for cardiovascular morbidity and mortality. Diabetic kidney disease (DKD) leads to altered lipid metabolism through insulin resistance, inflammation and oxidative stress resulting in an ...
Ann S. Forrest, Priyanka Majety, Stéphanie B. Mayer, Om P. Ganda   +3 more
wiley   +1 more source

Gut microbiome dysbiosis is associated with aldosterone overproduction in idiopathic hyperaldosteronism. [PDF]

iScience
Jiang Y, Zeng Q, Ma L, He Y, Zhu S, Xiong Y, Jing Y, Zhang Q, Qi S, Hu J, Li Q, Yang S.   +11 more
europepmc   +1 more source

Therapies for Cardiovascular‐Kidney‐Liver‐Metabolic Syndrome: Reappraisal of Fibrates

Diabetes, Obesity and Metabolism, Volume 28, Issue 12, Page 10931-10949, December 2026.
ABSTRACT Cardiovascular disease, chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), obesity and metabolic dysfunction‐associated steatohepatitis (MASH) frequently coexist and share overlapping pathophysiology, forming the proposed cardiovascular‐kidney‐liver‐metabolic (CKLM) syndrome.
Virginia Anagnostopoulou, Christoforos K. Travlos, Lucas Lage Marinho, Thomas A. Mavrakanas, João Pedro Ferreira, Abhinav Sharma   +5 more
wiley   +1 more source

Delayed diagnosis, greater disease burden: primary aldosteronism in a Brazilian cohort. [PDF]

J Endocr Soc
Montozo JL, Elias PCL, Alexandre AE, Molina CAF, Muglia VF, Elias J, Castro M, Moreira AC, Mermejo LM.   +8 more
europepmc   +1 more source

Monogenic Kidney Disorders as Hidden Drivers of Electrolyte Imbalance and Hypertension. [PDF]

Electrolyte Blood Press
Ahn YH.
europepmc   +1 more source